


Médica Sur recorded 18% sales growth (excluding COVID operations) compared to 3Q21, thus surpassing pre-pandemic results.

Mexico City. October 21 de 2022 – MEDICA, S.A.B. de C.V. ("Medica Sur," "MEDICA," the "Group," or "the Company") (BMV ticker symbols: MEDICAB and CEBURES MEDICA 20) reports its unaudited results for the third quarter of 2022 ("3Q22"). This information is presented in accordance with International Financial Reporting Standards ("IFRS").

- The Company's **total revenues** for the third quarter of 2022 amounted to Ps. 999.0 million, in line with the same quarter of the previous year. On a cumulative basis, total revenues were Ps. 2,950.7 million, a 2.8% growth compared to the same period of 2021. Notably, quarterly core business revenues expanded 18% compared to the third quarter of the previous year, while on a cumulative basis, increased 21% compared to the nine-month period of 2021.
- Operating income** totaled Ps. 162.9 million, a 20% decrease compared to the same quarter of the previous year. Operating margin in the quarter was 16.3%. This adjustment is the effect of a lower contribution to total revenues from COVID sales compared to the same quarter of the previous year, which was partially offset by increased operating income from the core business.

On a cumulative basis, the Company recorded an operating income of Ps. 495.8 million, a 20.6% decrease with respect to the same nine-month period of 2021, reflecting the items previously discussed above. The corresponding cumulative operating margin was 16.8%.

- EBITDA** for the third quarter stood at Ps. 214.6 million, compared to Ps. 426.8 million observed in the same period of the previous year. The EBITDA margin for 3Q22 was 21.5%. This effect was mainly due to the result of discontinued operations in the quarter of 2021.

For the first nine months of the year, EBITDA amounted to Ps. 1,175.3 million, an 8.6% decrease compared to the same period of the previous year, while the cumulative EBITDA margin was 39.8%. These results incorporate the effects from discontinued operations, which stood at Ps. 553.9 million.

- Net income** was Ps. 149.7 million in the third quarter of 2022, resulting in a net margin of 15.0%. This net result is 36.8% lower than the net income recorded in the same quarter of the previous year, driven by the effect of discontinued operations that took place in the same quarter of 2021.

The net income on a cumulative basis was Ps. 812.7 million, 16.9% higher than the figure reported in the 2021 period. Net margin was 27.5%. This includes the effects from discontinued operations totaling Ps. 396.1 million.

- At the end of 3Q22, **cash position** was Ps. 1,186.6 million, leading to a negative net debt of Ps. 186.6 million.

Médica Sur, S.A.B. de C.V. and Subsidiaries
Unaudited results

	Quarterly				Accumulated			
	3Q21	3Q22	Var (\$)	Var (%)	2021	2022	Var (\$)	Var (%)
Revenues	1,002.5	999.0	(3.5)	-0.3%	2,871.3	2,950.7	79.4	2.8%
Operating income	203.5	162.9	(40.6)	-20.0%	624.4	495.8	(128.6)	-20.6%
<i>Operating margin</i>	<i>20.3%</i>	<i>16.3%</i>		<i>-4.0 pp</i>	<i>21.7%</i>	<i>16.8%</i>		<i>-4.9 pp</i>
EBITDA*	426.8	214.6	(212.2)	-49.7%	1,285.8	1,175.3	(110.5)	-8.6%
<i>EBITDA* margin</i>	<i>42.6%</i>	<i>21.5%</i>		<i>-21.1 pp</i>	<i>44.8%</i>	<i>39.8%</i>		<i>-4.9 pp</i>
Consolidated net income*	236.9	149.7	(87.1)	-36.8%	695.2	812.7	117.6	16.9%
<i>Net margin*</i>	<i>23.6%</i>	<i>15.0%</i>		<i>-8.6 pp</i>	<i>24.2%</i>	<i>27.5%</i>		<i>3.3 pp</i>

Figures expressed in millions of Mexican pesos, including rounding effects.

** Figures including the effects of discontinued operations.*

■ Hospital Volume and Metrics 3Q22

- During the third quarter, Medica Sur had a total of 3,706 patients discharged to home, 8.6% more than the figure observed in the same quarter of the previous year.
- In the third quarter of 2022, the average inpatient stay decreased from 4.11 to 3.59 days, a 14.6% decrease compared to the third quarter of the previous year.
- Occupancy rate for the third quarter was 68.2%, a lesser ratio compared to the 70.7% occupancy seen in the same period of 2021.

Key events in 3Q22

• Renewal of Médica Sur's corporate image.

We continue to follow the tenets of the precept that has distinguished us, "Medical excellence with human warmth," to thereby offer a service based on an outstanding medical practice and human closeness.

Our new logo, seen as a symbol, captures visually our daily work with respect to our patients. It was inspired by our dynamism, harmony, and versatility. Additionally, it represents the values of Médica Sur, which are: ethics, professionalism, safety, sustainability and of course, our own staff. Thus, the focal point of all our tasks is always the patient himself.




Porque nuestro motivo eres TÚ.

• We were recognized by the Consejo Mexicano de Certificación en Enfermería A.C. ("COMCE") as the leading private hospital with the highest number of certified nursing personnel.

In line with our mission and vision regarding the care of life, health, and attention to patients, with a focus on hospital quality and warmth, we were recognized by COMCE in July of this year for maintaining 95% of our professional nursing staff certified in terms of the competencies, experience and ethical performance needed.

Médica Sur is the private hospital with the largest number of nursing staff certified by COMCE.

This news is highly satisfactory to us, given that it reflects our ongoing commitment of delivering the best possible care we can provide for our patients.



- **Significant Improvements in Médica Sur's credit ratings.**

Last October, HR Ratings de México, S.A. de C.V., ("HR Ratings") upgraded Médica Sur's HR AA+ rating to HR AAA, while maintaining a Stable Outlook for both Médica Sur and the issuance of MEDICA 20 bonds. Also, the HR1 rating for Médica Sur was upgraded to HR+1.

On July, Fitch México, S.A. de C.V. ("Fitch") upgraded Médica Sur's long-term national scale rating to 'AA (mex)' from 'AA-(mex)'. The rating outlook on the company was revised from Positive to Stable.

Both agencies emphasized the consistency of the Company's solid operating performance, featuring margins above 20%, which reflect the Company's ability to generate positive free cash flow (FCF) going forward. This strengthens the Company's financial profile.

HR Ratings Mexico

upgraded rating to:

↑ **HR AAA**
from HR AA+

Fitch Ratings Mexico

upgraded rating to:

↑ **'AA (mex)'**
from 'AA-(mex)' Sur

- **A dividend of Ps. 26.8330 per share was decreed at a general ordinary stockholders' meeting.**

Following the summons of the general ordinary stockholders' meeting dated August 10, 2008, the Meeting was carried out on August 26, 2022.

At the said meeting the payment of a dividend of Ps. 26.833 per share was decreed, for a total of Ps. 2,899,995,150.77, partially paid through the disposal of retained earnings for years prior to 2013.

This dividend was delivered in a single installment, beginning on September 7, 2022. Coupon number 27 was required to be submitted at the Company's domicile located at Puente de Piedra number 150, Col. Toriello Guerra, Alcaldía de Tlalpan, C.P. 14050, in Mexico City.

As for the shares on deposit at S.D. Indeval Institución para el Depósito de Valores, S.A. de C.V. (Mexico's central securities depository), the dividend was liquidated as of the same date previously mentioned.



RELEVANT SUBSEQUENT EVENT

- **Approval at the ordinary and extraordinary general shareholders' Meeting of the cancellation of repurchased shares.**

At the ordinary and extraordinary general shareholders' Meeting summoned last September 28, which was held on October 14, the Meeting resolved as follows.

- The stock reclassification of 53.2 million shares without affecting the ownership structure of the Company's shareholders
- The fixed portion reduction and corresponding increase of the variable portion of the capital stock, effective as of the date of the Meeting. The new distribution of the capital stock is as follows:

	Stock Reclassification	
	Previous	Current
Outstanding shares	123,281,750	123,281,750
Series B / Class I	53,530,464	238,054
Series B / Class II	69,751,286	123,043,696
Stockholders' equity	\$ 517,873,932.00	\$517,873,932.00
Fixed	\$ 228,054,589.00	\$ 1,000,000.00
Variable	\$ 289,819,343.00	\$516,873,932.00

- The cancellation of 15.3 million shares repurchased by the Company between 2017 and 2022. As a result, outstanding shares decreased from 123.2 to 107.9 million shares after the said operation.
- The shareholders will be informed by the Company about the procedure for the exchange of physical stock certificates.
- The resignation of proprietary and alternate members of the Board of Directors, as well as the ratification and appointment of other members, were approved.
- For further information, see section [800500] Notes – Major relevant events, and the summary of resolutions of shareholders' meetings 2022, within this quarterly report.

Scan or click to access the summary of the Extraordinary Meeting's resolutions



Scan or click to access the summary of the Ordinary Meeting's resolutions



Financial Summary 3Q22:

• Revenues

Total revenues for the third quarter of 2022 amounted to Ps. 999.0 million, in line with the figure recorded in the same period of the previous year. On a cumulative basis, revenues for the first nine months of the year were Ps. 2,950.7 million, a 2.8% increase compared to total revenues for the same period of 2021.

Quarterly revenues from the core business expanded 18% compared to the third quarter of the previous year, while on a cumulative basis, they grew 21% compared to the nine-month period of 2021. Below is 3Q22 information on contribution to total revenues by business units compared to 3Q21:

i) Hospital - Additional Ps. 90.8 million

- 3,706 patients discharged to home in 3Q22, an 8.6% increase over the same quarter of the previous year.
- Increase of 36.8% in the number of patients served in critical care units, while there was a 14.9% increase in the number of patients treated in the emergency unit, jointly with a 1.6% increase in the number of surgeries.
- This growth was partially impacted by lower activity in the care of critical and non-critical COVID patients, with a 300-patient reduction compared to the volume of 3Q21.

ii) Clinical Services and Diagnostic Units - Additional Ps. 42.7 million

The business unit observed a higher demand for services such as:


- 19% in chemotherapies at the Oncology Center.
- 13% additional studies in the Magnetic Resonance Unit.
- 114% Gamma Knife Radiosurgery procedures.
- 7% in PET-CT.
- 5% in Nuclear Medicine.

iii) Other – Additional Ps. 14.3 million

The strong performance in this segment was driven by:

- A higher influx of visitors to the cafeteria and restaurant concessions.
- Increased occupancy at the Holiday Inn hotel.
- Higher sales in external pharmacy.
- Expansion in medical office rental revenues.


As a result, core business revenues for 3Q22 grew Ps. 147.8 million, a figure partially offset by the decline in COVID revenues of Ps. 151.2 million compared to 3Q21.



• Operating income

Operating income totaled Ps. 162.9 million, a 20% decrease compared to the same quarter of the previous year. Operating margin in the quarter was 16.3%. This adjustment is the effect of a lower contribution to total revenues from COVID sales compared to the same quarter of the previous year, which was partially offset by increased operating income from the core business.

On a cumulative basis, the Company recorded an operating income of Ps. 495.8 million with an operating margin of 16.8%, a 20.6% decrease with respect to the same nine-month period of 2021, reflecting the items previously discussed above.



• Discontinued operations

During the period from January to September 2022 the company received proceeds in the amount of Ps. 607.1 million from Grupo SYNLAB International GmbH (Synlab), consisting of:


- Ps. 399.2 million related to the sale of the *Laboratorio Médico Polanco* business in compliance with the variable conditions agreed upon, to occur in 2022, which includes royalties from COVID revenues.
- Ps. 207.9 million from the sale of 20 branches of the Laboratorios Médica Sur brand, a transaction completed in April 2022.

The net effect of discontinued operations is Ps. 396.1 million in the 2022 period described above, after deducting expenses and taxes. For further information on Discontinued Operations, see the "[800500] discontinued operations" section of this report.

• EBITDA

EBITDA for the third quarter stood at Ps. 214.6 million, compared to Ps. 426.8 million observed in the same period of the previous year. The EBITDA margin for 3Q22 was 21.5%. This effect was mainly due to the result of discontinued operations in the quarter of 2021.

For the first nine months of the year, EBITDA amounted to Ps. 1,175.3 million, an 8.6% decrease compared to the same period of the previous year, while the cumulative EBITDA margin was 39.8%. These results incorporate the effects from discontinued operations, valued at Ps. 553.9 million.



• Taxes

The Company's taxes in 3Q22 resulted in a 2.9% increase compared to the same quarter of the previous year. This was the result of a higher pretax profit for the quarter.

• Comprehensive Cost of Financing ("CCF")


CCF for 3Q22 amounted to Ps. 35 million, reflecting a positive effect when compared to the same quarter of the previous year. This was due to an increase of Ps. 43.7 million in the interest income line, a result of a stronger cash position and higher interest rates in the quarter.

Figures in million pesos	3Q21	3Q22	Var (\$)	Var (%)
Foreign exchange profit (loss)	4.0	(0.2)	(4.2)	-104.7%
Interest expenses	(18.4)	(19.0)	(0.6)	3.4%
Interest income	10.5	54.2	43.7	415.2%
Comprehensive Cost of Financing	(3.9)	35.0	38.9	-1004%

• Net income

Net income was Ps. 149.7 million in the third quarter of 2022, resulting in a net margin of 15.0%. This net result is 36.8% lower than the net income recorded in the same quarter of the previous year, driven by the effect of discontinued operations that took place in the same quarter of 2021.

The net income on a cumulative basis was Ps. 812.7 million, 16.9% higher than the figure reported in the 2021 period. Net margin was 27.5%. This includes the effects from discontinued operations totaling Ps. 396.1 million.



• Negative net debt

As of September 30, 2022, the Company's total indebtedness was Ps. 1,000 million, consisting of the MEDICA 20 notes, with a fixed annual rate of 6.99% and paying interest semi-annually. The Company has satisfied all obligations under this debt issuance to date.

Médica Sur's cash position at the end of the third quarter was Ps. 1,186.6 million, leading to a negative net debt of Ps. 186.6 million.

Figures in million pesos	2021	3Q22	Var (\$)	Var (%)
Interest-bearing debt	1,000	1,000	-	-
Cash position	3,532	1,187	(2,345)	-66%
Net Debt	(2,532)	(187)		
Leverage	-1.4x	-0.1x		

(Net Debt / EBITDA LTM)

• Share repurchase fund

Details of the transactions that occurred in the third quarter of the year with respect to the operation of the share repurchase fund are as follows:

- Repurchase transactions of Ps. 21.9 million were carried out by the Group, resulting in the acquisition of 459.2 thousand shares.

The Company has repurchased 15.3 million of its own shares by using Ps. 468.2 million of the repurchase fund as of September 30, 2022. All the repurchased shares were cancelled following the resolutions adopted at the extraordinary general shareholders' meeting held on October 14, 2022. Therefore, the number of shares representing the Company's capital stock decreased from 123.2 million to 107.9 million shares outstanding.



Financial Statements (unaudited) (amounts in Mexican pesos)

Médica Sur, S.A.B. de C.V.

Balance Sheet as of December 31, 2021 and September 30, 2022

	2021	3Q22	Change %	Change \$
Assets	6,984,041,098	4,609,173,132	-34.0%	(2,374,867,965)
<i>Current assests</i>	<i>4,133,124,027</i>	<i>1,771,842,898</i>	<i>-57.1%</i>	<i>(2,361,281,129)</i>
Cash and Cash Equivalents	3,531,821,699	1,186,598,934	-66.4%	(2,345,222,765)
Accounts Receivable	448,248,511	415,381,448	-7.3%	(32,867,064)
Others Net Account Receivable	26,277,118	31,497,013	19.9%	5,219,895
Inventories	126,776,699	138,365,503	9.1%	11,588,805
<i>Property, Plant and Equipment (Net)</i>	<i>2,578,385,612</i>	<i>2,577,450,746</i>	<i>0.0%</i>	<i>(934,866)</i>
Property	2,934,576,637	2,961,970,267	0.9%	27,393,630
Industrial Machinery and Equipment	56,343,457	29,368,110	-47.9%	(26,975,347)
Other Equipment	937,662,055	668,387,632	-28.7%	(269,274,422)
Right-of-use asset	97,636,784	67,826,259	-30.5%	(29,810,525)
Accumulated Depreciation	(1,480,659,933)	(1,260,302,717)	-14.9%	220,357,216
Accumulated Depreciation Right-of-use asset	(33,957,774)	(22,178,021)	-34.7%	11,779,753
Constructions in Process	66,784,386	132,379,215	98.2%	65,594,829
<i>Investment properties</i>	<i>73,424,493</i>	<i>70,114,122</i>	<i>-4.5%</i>	<i>(3,310,371)</i>
Land	52,165,613	52,165,613	0.0%	-
Buildings	21,258,879	17,948,508	-15.6%	(3,310,371)
<i>Intangible Assets</i>	<i>199,106,966</i>	<i>189,765,366</i>	<i>-4.7%</i>	<i>(9,341,600)</i>
Total Liabilities	2,069,742,793	2,171,570,354	4.9%	101,827,562
<i>Current Liabilities</i>	<i>1,003,843,425</i>	<i>1,117,217,622</i>	<i>11.3%</i>	<i>113,374,197</i>
Suppliers	269,143,231	280,890,597	4.4%	11,747,366
Short-term securities Loans	19,416,667	1,941,667	-90.0%	(17,475,000)
Income tax payable	338,845,135	125,630,657	-62.9%	(213,214,478)
Other Current Liabilities	354,258,128	692,720,671	95.5%	338,462,543
Short-term lease liability	22,180,264	16,034,030	-27.7%	(6,146,234)
<i>Long-term Liabilities</i>	<i>1,065,899,368</i>	<i>1,054,352,732</i>	<i>-1.1%</i>	<i>(11,546,635)</i>
Accrued Interest	991,928,321	993,560,509	0.2%	1,632,188
Other Credits	30,968,955	30,299,952	-2.2%	(669,003)
Long-term lease liability	43,002,092	30,492,271	-29.1%	(12,509,821)
<i>Stockholders Equity</i>	<i>4,914,298,304</i>	<i>2,437,602,778</i>	<i>-50.4%</i>	<i>(2,476,695,525)</i>
<i>Non-Controlling Interest</i>	<i>955,639</i>	<i>955,639</i>	<i>0.0%</i>	<i>-</i>
<i>Equity attributable to Equity Holders of the Company</i>	<i>4,913,342,665</i>	<i>2,436,647,139</i>	<i>-50.4%</i>	<i>(2,476,695,525)</i>
Paid-in Capital Stock	517,873,932	517,873,932	0.0%	-
Premium in Share Placement	121,280,931	121,280,931	0.0%	-
Contributions for Future Capital Increases	124,628	124,628	0.0%	-
Retained earnings	2,705,744,785	564,894,050	-79.1%	(2,140,850,735)
Reserve for Share Buyback Program	422,517,711	428,410,115	1.4%	5,892,404
Income of the year	1,154,516,740	812,746,954	-29.6%	(341,769,786)
Other Comprehensive Income	(8,716,064)	(8,683,473)	-0.4%	32,591
Total Liabilities and Shareholders Equity	6,984,041,096	4,609,173,132	-34.0%	(2,374,867,964)

Amounts in accordance with IFRS



Financial Statements (unaudited) (amounts in Mexican pesos)

Médica Sur, S.A.B. de C.V.

Income Statements of the third quarter of 2021 and 2022

	3Q21	3Q22	Change %	Change \$
Revenues	1,002,519,923	999,048,144	-0.3%	(3,471,779)
Cost of Sales	(584,911,996)	(635,505,255)	8.6%	(50,593,259)
Gross Profit	417,607,927	363,542,889	-12.9%	(54,065,038)
Selling and Administrative Expenses	(217,234,593)	(200,865,853)	-7.5%	16,368,740
Other Operating Expenses	3,128,157	181,910	-94.2%	(2,946,247)
Operating Income	203,501,491	162,858,947	-20.0%	(40,642,545)
Foreign Exchange Gain (loss)	4,020,389	(187,687)	N.A.	(4,208,076)
Interest Expense	(18,419,641)	(19,046,729)	3.4%	(627,087)
Interest Income	10,526,683	54,235,385	415.2%	43,708,703
Income before Taxes	199,628,922	197,859,916	-0.9%	(1,769,006)
Income Tax Expense	(56,693,352)	(58,370,020)	3.0%	(1,676,668)
Continuous Operations Profit (loss)	142,935,569	139,489,896	-2.4%	(3,445,674)
Discontinued Operations Loss	93,917,692	10,251,371	-89.1%	(83,666,322)
Net Income	236,853,262	149,741,266	-36.8%	(87,111,996)
Non-Controlling Income	36,714	-	N.A.	(36,714)
Controlling Income	236,889,976	149,741,266	-36.8%	(87,148,710)

Amounts in accordance with IFRS

The financial information contained in this report was prepared in accordance with International Financial Reporting Standards (IFRS).

Financial Statements (unaudited) (amounts in Mexican pesos)

Médica Sur, S.A.B. de C.V.

Income Statements of the first nine-month period of 2021 and 2022

	2021	2022	Change %	Change \$
Revenues	2,871,258,910	2,950,653,603	2.8%	79,394,693
Cost of Sales	(1,703,620,517)	(1,870,608,276)	9.8%	(166,987,759)
Gross Profit	1,167,638,393	1,080,045,327	-7.5%	(87,593,066)
Selling and Administrative Expenses	(547,089,090)	(587,053,513)	7.3%	(39,964,423)
Other Operating Expenses	3,858,466	2,857,552	-25.9%	(1,000,914)
Operating Income	624,407,770	495,849,367	-20.6%	(128,558,403)
Foreign Exchange Gain (loss)	3,998,593	-1,854,392	N.A.	(5,852,985)
Interest Expense	(57,467,338)	(56,860,891)	-1.1%	606,447
Interest Income	19,708,376	162,303,083	N.A.	142,594,707
Income before Taxes	590,647,400	599,437,166	1.5%	8,789,766
Income Tax Expense	(179,734,218)	(182,768,345)	1.7%	(3,034,128)
Continuous Operations Profit (loss)	410,913,183	416,668,821	1.4%	5,755,638
Discontinued Operations Loss	284,237,256	396,078,134	39.3%	111,840,877
Net Income	695,150,439	812,746,954	16.9%	117,596,515
Non-Controlling Income	27,799	-	N.A.	(27,799)
Controlling Income	695,178,238	812,746,954	16.9%	117,568,716

Amounts in accordance with IFRS

The financial information contained in this report was prepared in accordance with International Financial Reporting Standards (IFRS).

Coverage by Analysts

Per the provisions of the internal regulations of the Mexican Stock Exchange (Bolsa Mexicana de Valores) outlined in section VIII of article 4.033.01 regarding maintenance requirements, we confirm that the brokerage houses that provide analysis coverage for our securities are *Grupo Bursátil Mexicano S.A. de C.V.*, *Casa de Bolsa* and *Miranda Global Research* (independent analyst).

About MEDICA

MEDICA, S.A.B. de C.V. (BMV: MEDICAB) is a hospital operator and an integrated provider of health care and related services. It offers these services through hospitals and laboratories. MEDICA brings together a group of physicians, medical professionals, nurses, hospital administration and operations. It aims to offer a service of medical excellence with human touch guided by a strict code of ethics and supported by state-of-the-art medical equipment and infrastructure.

EBITDA*

EBITDA is an indicator utilized in the financial analysis of the Company that is not recognized by the IFRS but is calculated based on the numbers derived from the Company's financial statements. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization.

For the 2021 and 2022 numbers, the EBITDA includes the effects of the IFRS 16 leases accounting standard.

EBITDA is not a financial indicator under IFRS, nor is it an indicator of liquidity or performance. We consider that EBITDA can be useful to facilitate comparisons of operating performance between periods on a combined basis, although other issuers may calculate these metrics differently.

EBITDA must not be interpreted as (i) an alternative to net income as an indicator of the Company's operating performance nor (ii) to the cash flow from operating activities as a measure of the Company's liquidity.

Forward-looking statements

This report contains forward-looking statements. Such statements include but are not limited to: (i) statements regarding our financial condition and operating results; (ii) statements regarding our plans, objectives, or targets, including statements concerning our activities; and (iii) statements regarding the underlying assumptions upon which those statements are based. Forward-looking statements contain words such as "intends," "anticipates," "considers," "estimates," "expects," "foresees," "plans," "predicts," "seeks," "could," "should," "possible," "guideline," and other similar terms, either in the first or third person. However, these are not the only terms used to identify these statements.

By their very nature, forward-looking statements involve risks and uncertainties of both a general and specific nature, including the risk that such predictions, forecasts, projections, and other forward-looking statements are not fulfilled. Investors are cautioned that many important factors may cause actual results to differ materially from those expressed in the plans, objectives, expectations, estimates, and statements, both expressed and implied, contained in the forward-looking statements.

The information related to future performance contained in this press release must be read jointly with the risks included in the "Risk Factors" section submitted to the National Banking and Securities Commission (CNBV; Comisión Nacional Bancaria y de Valores).



CONTACT

Investor Relations: **Arely Gutiérrez**

Ph: 52(55) 5424 7200 Ext. 3425: agutierrez@medicasur.org.mx

Visit the Investor Relations site: <https://inversionistas.medicasur.com.mx/>